Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Party season approaches; but first, conferences.
Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.
But could toxicity be holding back filing plans?
Syndax scored the first menin approval, but Kura is first with a licensing deal.
